Navigation Links
Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009
Date:7/30/2009

y statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the Company's ability to provide high quality services and facilitate personalized medicine, the success of the Company's business model, improving case volumes, increasing revenues, customer adoption and growth, the Company's capacity to manage and support future growth and ability to expand its business, hire additional personnel and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects and ability to capture additional market share in the U.S., estimated effective tax rates and the Company's financial guidance for 2009. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks, financial risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.<
'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Genoptix, Inc. to Announce Second Quarter 2009 Financial Results
2. Genoptix Announces Participation at the 29th Annual William Blair Growth Stock Conference
3. Genoptix Announces Participation at the Bank of America and Merrill Lynch 2009 Annual Health Care Conference
4. Genoptix Reports Strong Growth for the First Quarter of 2009
5. Genoptix, Inc. to Announce First Quarter 2009 Financial Results
6. Genoptix Announces Participation at the Cowen and Company 29th Annual Health Care Conference
7. Genoptix Announces Participation at Barclays Capital Global Healthcare Conference
8. Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009
9. Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
11. Genoptix Announces the Addition of New Members to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... VisitandCare.com , was designed to help doctors manage ... practices to boost patient conversion rates and clink revenue. ... a 60 percent increase in sales revenue and a ... one-of-a-kind CRM software in their own healthcare practices. , ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 For the ... IT security and network services company, has been named ... Inc. magazine's Inc. 5000 list highlights America's fastest growing ... year since the list inception in 2007. , Landing ... grown 144 percent over the past three years. , ...
(Date:9/2/2014)... (trade name: Betmiga) has been approved since December 2012 ... an early benefit assessment pursuant to the Act on ... the German Institute for Quality and Efficiency in Health ... added benefit over the appropriate comparator therapy specified by ... advantage with regard to side effects: Dry mouth was ...
(Date:9/2/2014)... A New York City based company is ... yet revolutionary, product that will have far-reaching, ... care costs for Americans. , REMIND-A-CAP™ is ... control in the user's hands. It's a simple device ... date of intake by simply turning a knob. No ...
Breaking Medicine News(10 mins):Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:CentraComm Named to Inc. 5000 for 8th Consecutive Year 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2
... first discovered in China nearly 5000 years ago, has ... heart disease, stroke and certain types of cancer. Researchers ... two compounds found in green tea, EGCG (epigallocatchin gallate) ... blocking the enzyme that destroys cartilage. Dr David Buttle, ...
... Venous thromboembolism is a condition which causes clotting in ... five- to 10-day course of heparin followed by three ... the problem with this treatment is that once the ... rates of this problem are reduced if the patient ...
... in the February issue of the British Medical Journal has ... at risk of heart disease later in life than those ... infant in Scotland during the years 1981-85, were identified as ... or repeated miscarriages. Then, during 1981 to 1999, the researchers ...
... a common problem in the knees, is a form ... change. A key problem involved in in these type ... salt called hyaluronan within the fluid that moisturizes the ... injections are being given to humans since 1987, after ...
... in appetite control, called ghrelin, has been identified by ... have demonstrated the effect of the hormone on the ... specialized neurons in the hypothalamus involved in weight regulation. ... the ability to stimulate feeding when introduced to specialized ...
... not all that well understood, but is believed to ... winter months. Winter depression involves suffering from feelings of ... and nights get shorter. Other SAD symptoms include overeating, ... than usual. Researchers have now found that light therapy// ...
Cached Medicine News:Health News:Treatment over a longer period for blood clotting 2Health News:Miscarriage during pregnancy and heart disease linked 2Health News:Scientists locate key hormone involved in appetite control 2
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... 2014 Donald Spector , a renowned ... 8,823,512 for a Wearable Biosensor, which will issue today, ... this field.  Mr. Spector holds some of the earliest ... made today by New York College of Health Professions, ... of world-class intellectual properties.  New York College noted that ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... AMN Healthcare Services, Inc. (NYSE: AHS ), the largest ... quarterly conference call to discuss third quarter results on Thursday, ... also expects to issue an earnings news release on Thursday, ... 4:00 p.m. Eastern Time. , A live webcast of the ...
... CPhI Worldwide and connected events - the global pharma ingredients and ... - 15 October for its 20th staging. , The co-located ... technology events are joined for 2009 under the Where Pharma ... The new platform markedly reflects the notable convergence of the pharma ...
Cached Medicine Technology:AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 3
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Lederer periosteal elevators....
Medicine Products: